Table 2.
Pre- and post-peptide receptor radioligand therapy prostate-specific antigen, response evaluation criteria in solid tumors sum of diameter and maximum standard uptake values and responses by various criteria
| PSA | RECIST SoD | Highest SUVmax | Responses by various criteria | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-PRLT | Post-PRLT | Pre-PRLT | Post-PRLT | Pre-PRLT | Post-PRLT | BR | RECIST | PERCIST | EORTC | MDA |
| 37.1 | 445.0 | 4.7 | 10.0 | 6.6 | 19.4 | PD | PD | PD | PD | PD |
| 550.0 | 344.0 | 4.3 | 4.1 | 46.4 | 92.6 | SD | SD | PD | PD | SD |
| 344.0 | 194.0 | 4.1 | 7.5 | 92.6 | 25.7 | SD | PD | PD* | PD* | SD |
| 194.0 | 204.0 | 7.5 | 12.0 | 25.7 | 58.9 | SD | PD | PD | PD | SD |
| 204.0 | 552.0 | 12.0 | 16.4 | 58.9 | 43.8 | PD | PD | PD* | PD* | SD |
| 23.5 | 5.4 | 2.0 | 1.7 | 99.5 | 58.5 | PR | SD | PR | PR | SD |
| 5.4 | 8.9 | 1.7 | 1.7 | 58.5 | 58.7 | PD | SD | SD | SD | SD |
| 8.9 | 9.3 | 1.7 | 2.1 | 58.7 | 30.3 | SD | SD | PR | PR | SD |
| 9.3 | 222.1 | 2.1 | 4.8 | 30.3 | 13.7 | PD | PD | PD* | PD* | SD |
| 109.0 | 68.0 | 2.0 | 1.4 | 13.7 | 16.8 | SD | PR | SD | SD | SD |
| 179.0 | 45.6 | 1.8 | 1.6 | 38.0 | 23.2 | PR | SD | PR | PR | SD |
| 45.6 | 66.0 | 1.6 | 1.2 | 23.2 | 16.0 | PD | SD | PR | PR | SD |
| 66.0 | 165.0 | NM | NM | 16.0 | 18.2 | PD | SD | SD | SD | SD |
| 165.0 | 494.0 | NM | NM | 18.2 | 12.9 | PD | SD | SD | SD | SD |
| 119.0 | 70.0 | 4.3 | 4.0 | 29.7 | 24.7 | SD | SD | SD | SD | SD |
| 70.0 | 62.8 | 4.0 | 3.5 | 24.7 | 25.4 | SD | SD | SD | SD | SD |
| 62.8 | 42.7 | 3.5 | NM | 25.4 | 28.7 | SD | PR | SD | SD | SD |
| 42.7 | 31.2 | NT | NM | 28.7 | 22.7 | SD | SD | SD | SD | SD |
| 119.0 | 21.6 | 3.4 | 3.5 | 42.5 | 36.4 | PR | SD | SD | SD | SD |
| 21.6 | 23.0 | 3.5 | 3.5 | 36.4 | 17.6 | SD | SD | PR | PR | PR |
| 23.0 | 23.4 | 3.1 | 2.6 | 19.6 | 18.2 | SD | SD | SD | SD | SD |
| 23.4 | 95.2 | 2.6 | 2.3 | 18.2 | 32.2 | PD | SD | PD | PD | SD |
| 196.7 | 279.0 | NM | NM | 9.4 | 16.7 | PD | SD | PD | PD | SD |
PSA: Prostate-specific antigen, PRLT: Peptide receptor radioligand therapy, BR: Biochemical response, RECIST: Response evaluation criteria in solid tumors, PERCIST: Positron-emission tomography response evaluation criteria in solid tumors, EORTC: European organization for research and treatment of cancer, MDA: MD Anderson criteria, SoD: Sum of diameter, NM: Nonmeasurable, NT: Nontarget, PD: Progressive disease, *PD: Progressive disease due to new PSMA avid lesion despite decrease in highest SUVmax, PR: Progressive disease, SD: Stable disease, SUVmax: Maximum standard uptake value